MGC Pharmaceuticals Ltd (LON:MXC) has advised that is has released its 30 June 2023, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange’s Listing Rules.
MGC Pharmaceuticals Limited (LON:MXC) is a next-generation Pharma licensed company at the forefront of the emerging global plant-inspired pharmaceutical market.
Argent BioPharma Ltd (ASX:RGT), an innovative drug discovery company within the biopharmaceutical sector, has formally changed its name from MGC Pharmaceuticals Limited (ASX:MXC) to Argent BioPharma Limited as approved by shareholders at a General Meeting held
oduction and development of innovative medicines for unmet medical needs, has announced that following shareholder approval at a General Meeting held on 25 October 2023, the consolidation of the Company’s total issued capital on a 1:1,000
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval for a new share placement secured
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral
MGC Pharmaceuticals’ Roby Zomer discusses what the company does, the first import of Psilocybin, highlights from the last quarter and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.
MGC Pharmaceuticals plc (LON:MXC) CEO Roby Zomer joins DirectorsTalk Interviews to discuss the granting of its first import permit for 200g of Psilocybin Raw Mushroom material. In this interview Roby reminds us of what the company does,
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced it has been granted its first import permit for 200g of Psilocybin Raw Mushroom material to
MGC Pharmaceuticals Ltd (LON:MXC), a European based pharmaceutical company specialising in the production and development of plant derived medicines, has provided its Quarterly Activity Report for the three months ending 30th June 2023. Key Highlights: · CannEpil®, MGC
Early adopter in this space is MGC Pharmaceuticals (ASX:MXC), has positioned itself as a key player in pioneering psychedelic research and development. What a time to be alive. As the clock struck midnight to herald the start
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has welcomed the new regulation in Australia making it the first country to allow psychiatrists to prescribe psychedelics to
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced the appointment of Mr. Layton Mills as a Non-Executive Director of the Company effective immediately. Mr. Mills
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced that CannEpil®, MGC Pharma’s IMP has now been successfully imported and received by its first patients in
MGC Pharmaceuticals Ltd (ASX:MXC), a European based pharmaceutical company specialising in production and development of plant inspired medicines, has announced the following changes to the Board and its lead UK advisers, as a further development in its pharmaceutical
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.